In a cirrhotic patient with a single liver nodule ≥2 cm that demonstrates classic arterial‑phase hyperenhancement and portal‑venous wash‑out on multiphase CT or MRI, what are the indications, contraindications, risks, and pitfalls of performing a percutaneous liver biopsy?

Percutaneous Liver Biopsy in Cirrhotic Patients with ≥2 cm Nodules Showing Classic HCC Features

Primary Recommendation

In a cirrhotic patient with a single liver nodule ≥2 cm demonstrating arterial-phase hyperenhancement and portal-venous washout on multiphasic CT or MRI, percutaneous liver biopsy is NOT indicated because the lesion can be confidently diagnosed as HCC on imaging alone. 1, 2

---

Indications for Biopsy (When NOT to Rely on Imaging Alone)

Biopsy should be performed in the following specific scenarios:

Atypical Imaging Features

• Absence of classic vascular pattern: Lesions that are iso- or hypovascular in the arterial phase, or show arterial hyperenhancement without portal-venous washout 1
• Targetoid appearance: Rim enhancement or peripheral globular enhancement on arterial phase 1
• Marked T2 hyperintensity: Suggests possible hemangioma or other non-HCC pathology 1
• Targetoid features on diffusion-weighted imaging: Raises suspicion for intrahepatic cholangiocarcinoma 1

Patient-Specific Factors

• Non-cirrhotic patients: Imaging criteria are validated only for cirrhotic patients with chronic hepatitis B, chronic hepatitis C, or established cirrhosis 1, 2
• Discordant imaging results: When multiple imaging modalities provide conflicting findings 2
• Need for systemic therapy: Pathological confirmation should be obtained before initiating systemic treatment 1

Clinical Decision-Making Scenarios

• Patient not a transplant candidate: When the patient has decompensated cirrhosis (Child B8 or worse) and is not eligible for liver transplantation, biopsy may not alter management 1
• Serious comorbidities: When the patient cannot tolerate any form of HCC-specific therapy 1
• Multidisciplinary team recommendation: Every biopsy decision should be discussed by the hepatobiliary multidisciplinary team 1

---

Contraindications to Percutaneous Liver Biopsy

Absolute Contraindications

• Uncooperative patient: Unable to follow breath-holding instructions 1
• Severe coagulopathy: Uncorrectable bleeding diathesis 1
• No safe biopsy route: Lack of safe percutaneous access to the lesion 1

Relative Contraindications

• Decompensated cirrhosis with transplant candidacy: In patients on the liver transplant waiting list, biopsy may be unnecessary and carries seeding risk 1
• Lesion amenable to resection with acceptable risk: When the patient is a surgical candidate and resection can be performed safely, biopsy may be omitted and diagnosis made on the resection specimen 1
• Ascites: Increases technical difficulty and bleeding risk 1

---

Risks and Complications

Needle-Tract Seeding

• Incidence: Occurs in 1-3% of procedures 2
• Clinical impact: Does not significantly impact overall survival 2
• Time to seeding: Median interval of 17 months between biopsy and seeding (range 0-11% across studies) 1
• Risk mitigation: This low rate should not deter biopsy when clinically indicated 2

Bleeding Complications

• Frequency: Infrequent and generally manageable 2
• Risk factors: Coagulopathy, thrombocytopenia, ascites 1

False-Negative Results

• Sampling error: More common in small lesions and heterogeneous tumors 2
• Management: If biopsy is negative but imaging remains suspicious, perform close follow-up with imaging every 3-6 months 1, 2
• Repeat biopsy: Indicated if the lesion enlarges or changes enhancement pattern during surveillance 1, 2

---

Critical Pitfalls to Avoid

Diagnostic Pitfalls

• Misdiagnosis of non-HCC malignancies: The classic HCC imaging pattern (arterial hyperenhancement with washout) can also be seen in intrahepatic cholangiocarcinoma, hepatocellular adenoma, hepatic epithelioid angiomyolipoma, and metastases from neuroendocrine or gastrointestinal stromal tumors 3
• False-positive imaging: Imaging criteria carry a 5-10% false-positive rate 2
• Hemangioma mimicry: Lesions with marked T2 hyperintensity should not be diagnosed as HCC based on washout alone 1

Technical Pitfalls

• Biopsy of nodules <1 cm: Do not biopsy sub-centimeter nodules due to high false-negative rate, technical difficulty, and seeding risk; instead, perform surveillance ultrasound every 3-6 months 2, 4
• Relying on AFP alone: AFP has insufficient sensitivity (22-41% for small tumors) and should never replace imaging 1, 4

Management Pitfalls

• Unnecessary biopsy in typical cases: For nodules ≥2 cm with classic imaging features in cirrhotic patients, biopsy adds no diagnostic value and only introduces risk 1, 2
• Ignoring negative biopsy with suspicious imaging: A negative biopsy does not rule out malignancy; maintain close imaging surveillance 1, 2

---

Diagnostic Performance of Imaging vs. Biopsy

Imaging Specificity and Sensitivity

• Specificity: 91-100% for nodules ≥2 cm showing classic features 1, 2
• Sensitivity: 65-89% for nodules ≥2 cm, but only 41-62% for nodules 1-2 cm 1
• Single imaging modality: Sufficient for diagnosis in nodules ≥2 cm with typical features 1

Size-Specific Diagnostic Approach

• ≥2 cm nodules: One imaging study (CT or MRI) showing arterial hyperenhancement and washout is diagnostic 1, 2
• 1-2 cm nodules: Two concordant imaging studies recommended due to lower sensitivity 1, 2
• <1 cm nodules: Surveillance only; no immediate biopsy 1, 2

---

When Biopsy Results Are Negative but Suspicion Remains High

Follow-Up Protocol

• Imaging surveillance: Every 3-6 months with multiphasic CT or MRI 1, 2
• Repeat biopsy indications: Lesion enlargement or change in enhancement pattern 1, 2
• Duration of surveillance: Continue until the nodule disappears, displays diagnostic HCC characteristics, or requires intervention 1

Return to Routine Surveillance

• Stable nodules <1 cm: If stable for 12 months, return to routine 6-monthly surveillance 2